This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $461.46, signifying a -1.62% move from its prior day's close.
Company News for Dec 12, 2023
by Zacks Equity Research
Companies In The News Are: M, CI, HUM, OXY, HAS.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Why Is Humana (HUM) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold Humana (HUM) Stock for Now
by Zacks Equity Research
Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.
Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles
by Kaibalya Pravo Dey
The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.
Time to Buy Cigna (CI) or Humana's (HUM) Stock on News of a Potential Merger?
by Shaun Pruitt
News of a potential mega-merger between Cigna (CI) and Humana (HUM) made headlines in today's trading session and investors may be wondering if now is a good time to buy stock in these health giants.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Humana (HUM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Stocks Set to Gain From Growing Membership, Tech Advancements
by Debasmita Chatterjee
Rising premiums, contract wins, a telehealth services suite and the M&A strategy are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from encouraging industry prospects.
Humana's (HUM) CenterWell Unit Plans Expansion in Indiana
by Zacks Equity Research
Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.
Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.
Here's Why Humana (HUM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.
Humana (HUM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Humana (HUM) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Humana (HUM) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 8.81% and 0.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $515.48, signifying a -1.09% move from its prior day's close.
Humana (HUM) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Humana (HUM) settling at $519.87, representing a -0.83% change from its previous close.
Why Humana (HUM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.